All-cause and COVID-19 mortality in Qatar during the COVID-19 pandemic
暂无分享,去创建一个
L. Abu-Raddad | R. Bertollini | Asma Alnuaimi | M. Al-Thani | Z. Al-Kanaani | A. Butt | A. Al-khal | H. Al-Romaihi | M. Abdulmalik | S. Semaan | A. Latif | H. Chemaitelly | A. Kaleeckal | S. AlMukdad
[1] Gheyath K Nasrallah,et al. Protection against Reinfection with the Omicron BA.2.75 Subvariant , 2023, The New England journal of medicine.
[2] Gheyath K Nasrallah,et al. Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study , 2022, The Lancet Infectious Diseases.
[3] Gheyath K Nasrallah,et al. Protective Effect of Previous SARS-CoV-2 Infection against Omicron BA.4 and BA.5 Subvariants , 2022, The New England journal of medicine.
[4] Gheyath K Nasrallah,et al. Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections , 2022, The New England journal of medicine.
[5] L. Abu-Raddad,et al. Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild-to-moderate SARS-CoV-2 in Qatar , 2022, International Journal of Infectious Diseases.
[6] L. Abu-Raddad,et al. Type 2 diabetes epidemic and key risk factors in Qatar: a mathematical modeling analysis , 2022, BMJ Open Diabetes Research & Care.
[7] Gheyath K Nasrallah,et al. Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar , 2022, Nature Communications.
[8] Gheyath K Nasrallah,et al. Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar , 2022, The New England journal of medicine.
[9] Gheyath K Nasrallah,et al. Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage , 2022, Nature Communications.
[10] L. Abu-Raddad,et al. Efficacy of Natural Immunity against SARS-CoV-2 Reinfection with the Beta Variant , 2021, The New England journal of medicine.
[11] Gheyath K Nasrallah,et al. Introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and reinfections in Qatar: A nationally representative cohort study , 2021, PLoS medicine.
[12] L. Abu-Raddad,et al. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar , 2021, Nature Medicine.
[13] L. Abu-Raddad,et al. Characterizing epidemiology of prediabetes, diabetes, and hypertension in Qataris: A cross-sectional study , 2021, PloS one.
[14] L. Abu-Raddad,et al. SARS-CoV-2 infection hospitalization, severity, criticality, and fatality rates in Qatar , 2021, Scientific Reports.
[15] L. Abu-Raddad,et al. Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar , 2021, medRxiv.
[16] Gheyath K Nasrallah,et al. SARS-CoV-2 Infection Is at Herd Immunity in the Majority Segment of the Population of Qatar , 2021, Open forum infectious diseases.
[17] L. Abu-Raddad,et al. Herd Immunity against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 10 Communities, Qatar , 2021, Emerging infectious diseases.
[18] Gheyath K Nasrallah,et al. SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy , 2021, EClinicalMedicine.
[19] Gheyath K Nasrallah,et al. COVID-19 risk score as a public health tool to guide targeted testing: A demonstration study in Qatar , 2021, medRxiv.
[20] J. Tuomilehto,et al. A diabetes risk score for Qatar utilizing a novel mathematical modeling approach to identify individuals at high risk for diabetes , 2021, Scientific Reports.
[21] Gheyath K Nasrallah,et al. SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals , 2021, iScience.
[22] R. Bertollini,et al. Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to COVID-19 , 2020, medRxiv.
[23] L. Abu-Raddad,et al. Epidemiological investigation of the first 5685 cases of SARS-CoV-2 infection in Qatar, 28 February–18 April 2020 , 2020, BMJ Open.
[24] R. Irizarry,et al. Every Body Counts: Measuring Mortality From the COVID-19 Pandemic , 2020, Annals of Internal Medicine.
[25] R. Bertollini,et al. Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic , 2020, Scientific Reports.
[26] L. Abu-Raddad,et al. Preventing type 2 diabetes mellitus in Qatar by reducing obesity, smoking, and physical inactivity: mathematical modeling analyses , 2019, Population Health Metrics.
[27] A. El-Menyar,et al. Epidemiological and clinical characteristics of fall-related injuries: a retrospective study , 2019, BMC Public Health.
[28] D. Atar,et al. Heat Stress Impacts on Cardiac Mortality in Nepali Migrant Workers in Qatar , 2019, Cardiology.
[29] R. Latifi,et al. Predictors and Time-Based Hospital Mortality in Patients with Isolated and Polytrauma Brain Injuries , 2018, World Journal of Surgery.
[30] Martin O'Flaherty,et al. Forecasting the burden of type 2 diabetes mellitus in Qatar to 2050: A novel modeling approach. , 2017, Diabetes research and clinical practice.
[31] R. Mamtani,et al. Migrants, healthy worker effect, and mortality trends in the Gulf Cooperation Council countries , 2017, PloS one.
[32] A. Hyder,et al. Epidemiology of occupational injuries by nationality in Qatar: Evidence for focused occupational safety programmes. , 2015, Injury.
[33] E. Sadoun,et al. Change in the structures, dynamics and disease-related mortality rates of the population of Qatari nationals: 2007–2011 , 2013, Journal of epidemiology and global health.
[34] A. Ghaffar,et al. Trends in childhood trauma mortality in the fast economically developing State of Qatar , 2011, World journal of pediatrics : WJP.
[35] Peter C. Austin,et al. Using the Standardized Difference to Compare the Prevalence of a Binary Variable Between Two Groups in Observational Research , 2009, Commun. Stat. Simul. Comput..
[36] Abdulbari Bener,et al. The neglected epidemic: Road traffic accidents in a developing country, State of Qatar , 2005, International journal of injury control and safety promotion.
[37] C. Y. Li,et al. A review of the healthy worker effect in occupational epidemiology. , 1999, Occupational medicine.
[38] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .